Mérieux Equity Partners Invest EUR 40 mln in Swixx Biopharma – The Advisors

Mérieux Equity Partners, France (MxEP) has agreed to invest EUR 40 million into Swixx Biopharma, Switzerland (Swixx), taking a minority position. SIX listed HBM Healthcare Investments who had invested in Swixx in 2017, will co-invest alongside Mérieux, increasing HBM’s investment in Swixx by EUR 5 million. MxEP has arrangements in place to increase its investment in Swixx up to EUR 90 million, based upon the realization of certain milestones.

In this transaction Walder Wyss acted as legal counsel to Swixx Biopharma (Swixx), Switzerland with a team led by Markus Vischer (Partner, Corporate/M&A, team leader, pictured) and Nico Bernhard (Senior Associate, Corporate/M&A) and further included Timon Nydegger and Michael Kissling (both Associates Corporate/M&A).

Baker McKenzie acted as legal counsel for Mérieux Equity Partners (MxEP) with a team led by Alexander Fischer (Zurich) and Stephane Davin (Paris) with support from Boris Wenger, Roger Thomi, Julia Schieber, Susanne Liebel-Kotz, Selina Many, Raphael Schneuwly and Eylem Kutay (all Zurich) and Guillaume Le Camus, François-Xavier Naime, Robin Gaulier, Charles Baudoin (all Paris).

The new capital will be used to leverage the steady growth that Swixx has enjoyed over the past few years. The company operates fully owned subsidiaries across Central and Eastern Europe, Greece, and Russia. With 600 employees and sales exceeding EUR 260 million in 2021, Swixx is one of the largest and fastest-growing dedicated commercialization platform for biopharma and self-medication innovative companies in Central Eastern Europe.

 

FabioAdmin

SHARE